100% tevredenheidsgarantie Direct beschikbaar na betaling Zowel online als in PDF Je zit nergens aan vast
logo-home
Summary Health Economic Modeling (University of Twente) €7,16
In winkelwagen

Samenvatting

Summary Health Economic Modeling (University of Twente)

 4 keer bekeken  0 keer verkocht

Summary of the course Health Economic Modeling of the master Health Sciences..

Voorbeeld 4 van de 31  pagina's

  • 10 november 2024
  • 31
  • 2024/2025
  • Samenvatting
Alle documenten voor dit vak (1)
avatar-seller
jcgroos
Health Economic Modeling
Lecture 1 Introduction
Remember of previous years

- Concepts of utilities and QALYs
 Utility = the measure of the preference or value that an individual
or society gives a particular health state (often between 0 and 1).
 QALYS = the quality-adjusted life year is a generic measure of
disease burden, including both the quality and the quantity of life
lived. One QALY equates to one year in perfect health. 1 year of
life lived in a situation with utility 0.5 yields 0.5 QALYs.
- Estimation of the incremental cost effectiveness ratio (ICER)
 ICER: An incremental cost-effectiveness ratio is a summary
measure representing the economic value of an intervention,
compared with an alternative (comparator)
Cost A −Cost B
 ICER=
Effect A −Effect B❑
- Simple approaches to modelling (decision tree)

Health economic evaluations  involves a comparative analysis of two or
more alternative investment options (two interventions), to perform an
incremental cost-effectiveness analysis

When looking at a new innovation, consider: safety, costs, effectiveness,
willingness of health care professionals and patients to use it, availability,
comparison to previous methods

Types of healthcare decisions

1. Market approval decisions (EU regulations)
2. Market access and pricing decisions, e.g. for new pharmaceuticals
(companies)
3. Reimbursement of new pharmaceuticals and medical devices (ZIN,
national insurance, minister of health)
4. Physicians deciding about medical treatments (physician/patient)

Development to clinical use:

,Hierarchy of clinical evidence:

Expert opinions < non-experimental studies < quasi-experimental studies
< controlled studies without randomization < well performed RCTs <
systematic reviews of well performed RCTs

Development of a value dossier (see figure)

1. Collecting all evidence (systematic review)
2. Synthesizing the evidence  meta-analysis, health economic model
3. Interpreting the health economic outcomes
 In this subject we focus on step 2 and 3



3 questions

- Why do we allow drugs on the market, and reimburse drugs, for
which effectiveness is uncertain?  patients often want every drug
which could work if it is safe, the company has invested a lot of
money in development and we want companies to keep offering
their developments to the country (national interest)
- Which aspects/outcomes typically are the most uncertain when the
cost-effectiveness of a drug is first assessed?  (side-)effects and
effectiveness on the long-term
- When is an innovation or drug too expensive?  if the benefits are
too small compared to costs or when it is unaffordable (budget
impact too high)

Other major challenge in healthcare for the next decades  healthcare
personnel shortage

National healthcare institute (ZIN)  uses an evaluation procedure for new
drugs

, - Pharmacotherapeutic evidence (does it work)  clinical trial data,
systematic review meta-analysis
- Budget impact analysis (is it very cheap)  linear model
- Cost-effectiveness analysis (is it worth the price)  advanced model
estimating lifetime health effects and costs



Simulation modeling  simulation models can be useful alternatives to
randomized controlled trials (RCTs) for assessing the impact of
interventions, for example when:

- Evidence on long term costs and health effects is required
- Decisions need to be based on incomplete evidence
- Evidence on intermediate outcomes needs to be linked to long-term
health effects and costs
- Health economic results need to be generalized to other
settings/countries
- Interventions need to be compared that were never evaluated
directly with each other



Time horizon in simulation modeling  Time period over which the effects
(positive and negative) are calculated. In most situations there are
potential lifelong effects, so a lifetime time horizon is used.

Amount of evidence in simulation modeling  First clinical trials assessing
effectiveness typically have very limited follow-up (e.g. 3-12 months. This
gives no information on long-term effects. The data can be extrapolated.

Model complexity in simulation modeling  determining optimal model
complexity can be challenging. Too simple models don’t adequately reflect
evidence or clinical practice, while too complex models are hard to
understand and may require too many assumptions.

, Lecture 2
Example of a simple Markov Model:




Transition matrix of a Markov Model:




Example of a Markov model with cohort simulation:

Voordelen van het kopen van samenvattingen bij Stuvia op een rij:

Verzekerd van kwaliteit door reviews

Verzekerd van kwaliteit door reviews

Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!

Snel en makkelijk kopen

Snel en makkelijk kopen

Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.

Focus op de essentie

Focus op de essentie

Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!

Veelgestelde vragen

Wat krijg ik als ik dit document koop?

Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.

Tevredenheidsgarantie: hoe werkt dat?

Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.

Van wie koop ik deze samenvatting?

Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper jcgroos. Stuvia faciliteert de betaling aan de verkoper.

Zit ik meteen vast aan een abonnement?

Nee, je koopt alleen deze samenvatting voor €7,16. Je zit daarna nergens aan vast.

Is Stuvia te vertrouwen?

4,6 sterren op Google & Trustpilot (+1000 reviews)

Afgelopen 30 dagen zijn er 56326 samenvattingen verkocht

Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen

Start met verkopen
€7,16
  • (0)
In winkelwagen
Toegevoegd